Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) was the recipient of a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 106,400 shares, a decline of 62.1% from the March 15th total of 280,600 shares. Based on an average trading volume of 354,300 shares, the short-interest ratio is presently 0.3 days.
Analyst Upgrades and Downgrades
Several research analysts recently commented on CLPBY shares. Sanford C. Bernstein raised Coloplast A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 28th. Royal Bank of Canada upgraded shares of Coloplast A/S from a “hold” rating to a “moderate buy” rating in a research report on Monday, March 3rd.
Read Our Latest Research Report on CLPBY
Coloplast A/S Stock Up 0.5 %
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.01). Coloplast A/S had a net margin of 17.81% and a return on equity of 28.60%. On average, sell-side analysts anticipate that Coloplast A/S will post 0.31 EPS for the current fiscal year.
About Coloplast A/S
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.
Further Reading
- Five stocks we like better than Coloplast A/S
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk
- The How And Why of Investing in Oil Stocks
- Rocket Lab’s Growth Potential Gains Altitude on Defense News
- The Basics of Support and Resistance
- Goldman Sachs Just Revealed What’s Next for Markets
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.